Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 50268-875

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 50268-875). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

50 (873 15)

50 (873 15)
Venlafaxine Hydrochloride Extended-Release Capsules USP 37.5 mg, oral extended-release capsules, labeled for Rx only. The packaging contains 50 capsules in 5 blister packs of 10 unit doses each. Manufactured for AvPAK, Pulaski, TN, with a barcode and storage instructions included.*
FDA Label Image

50 (874 15)

50 (874 15)
Label for Venlafaxine Hydrochloride Extended-Release Capsules USP 75 mg by AvPAK, showing the dosage form as extended-release capsules. The label indicates a package containing 50 tablets (5x10) and includes storage instructions and a pharmacist note to dispense the Medication Guide. The manufacturer location, barcode, and revision dates are also visible.*
FDA Label Image

50 (875 15)

50 (875 15)
Label for Venlafaxine Hydrochloride Extended-Release Capsules USP, 150 mg, oral extended-release capsules. The label indicates a package of 50 tablets (5 bottles of 10), marked Rx Only. It includes instructions to dispense the Medication Guide to the pharmacist, dosage equivalents, storage instructions, and the AvPAK labeler information from Pulaski, TN.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A scatter plot chart showing fold change and 90% confidence intervals in pharmacokinetic parameters (Cmax, AUC) for venlafaxine in various special populations, including hepatic cirrhosis, mild/moderate impairment, renal impairment, hemodialysis, CYP2D6 polymorphism, age over 60, and gender. The X-axis represents change relative to a reference value.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A scatter plot with error bars illustrating fold change and 90% confidence intervals for venlafaxine analyte pharmacokinetics (Cmax, AUC) when interacting with various drugs including ethanol, diazepam, cimetidine, ketoconazole (in CYP2D6 EM's and PM's), indinavir, metoprolol, imipramine, and lithium. The x-axis shows change relative to a reference value from 0 to 3.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A chart illustrating the fold change and 90% confidence intervals of pharmacokinetic (PK) parameters Cmax and AUC for various analytes when interacted with different drugs including ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium. The fold changes are plotted relative to a reference value on the x-axis.*
FDA Label Image

Venlafaxinestructure (Venlafaxinestructure)

Venlafaxinestructure (Venlafaxinestructure)
Chemical structure of Venlafaxine Hydrochloride, showing a cyclohexanol group attached to a methoxyphenyl ring, with a chiral center indicated in the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.